ANI Pharmaceuticals introduced its first extended‑release generic of carbamazepine, a medication used for epilepsy and trigeminal neuralgia, in 100‑mg, 200‑mg and 300‑mg capsule strengths. The product, a generic version of the reference‑listed drug Carbatrol®, is positioned to capture a share of the U.S. market, which IQVIA estimates at roughly $65 million in annual sales.
The launch expands ANI’s generics portfolio and reinforces the cash‑generating foundation that underpins its rare‑disease growth strategy. By adding a limited‑competition product, ANI aims to increase its generics revenue mix while maintaining high manufacturing standards at its U.S. facilities. The company plans to introduce 10–15 new generic products each year, underscoring its commitment to sustaining cash flow for rare‑disease investments.
ANI’s rare‑disease segment is expected to represent about 60 % of total net revenues in 2026, with the company’s flagship asset Cortrophin Gel driving significant growth. In 2025, ANI reported record net revenues of $883.4 million, a 43.8 % year‑over‑year increase, and adjusted non‑GAAP EBITDA of $65.4 million in Q4, up 30.6 % from the prior year. The generics launch is therefore a material operational milestone that supports the company’s broader transformation from a commodity generics producer to a high‑growth specialty‑pharma business.
"Continuing to strengthen our Generics portfolio through strategic product launches remains a key priority for us," said ANI President and CEO Nikhil Lalwani. "The launch of Carbamazepine Extended‑Release Capsules, another limited‑competition product, highlights our continued commitment to improving patient access to essential medicines while maintaining the highest standards of quality and compliance."
The introduction of the extended‑release formulation offers patients less frequent dosing and positions ANI to capture a stable revenue stream in a niche market. The limited‑competition nature of the product reduces pricing pressure, while the company’s focus on high manufacturing standards ensures product quality and regulatory compliance. Together, these factors strengthen ANI’s cash generation capacity, enabling continued investment in its rare‑disease pipeline and supporting the company’s strategic shift toward specialty pharmaceuticals.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.